ATE372785T1 - Verfahren zur verabreichung von arzneimitteln mit bindungsaffinität zum plasmaprotein und verwendung der zusammensetzung in dem verfahren - Google Patents

Verfahren zur verabreichung von arzneimitteln mit bindungsaffinität zum plasmaprotein und verwendung der zusammensetzung in dem verfahren

Info

Publication number
ATE372785T1
ATE372785T1 AT00940773T AT00940773T ATE372785T1 AT E372785 T1 ATE372785 T1 AT E372785T1 AT 00940773 T AT00940773 T AT 00940773T AT 00940773 T AT00940773 T AT 00940773T AT E372785 T1 ATE372785 T1 AT E372785T1
Authority
AT
Austria
Prior art keywords
plasma protein
binding affinity
drugs
administration
drug
Prior art date
Application number
AT00940773T
Other languages
English (en)
Inventor
Keiichi Kawai
Norito Takamura
Ryuichi Nishii
Original Assignee
Nihon Mediphysics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Mediphysics Co Ltd filed Critical Nihon Mediphysics Co Ltd
Application granted granted Critical
Publication of ATE372785T1 publication Critical patent/ATE372785T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00940773T 1999-06-21 2000-06-21 Verfahren zur verabreichung von arzneimitteln mit bindungsaffinität zum plasmaprotein und verwendung der zusammensetzung in dem verfahren ATE372785T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17351499 1999-06-21

Publications (1)

Publication Number Publication Date
ATE372785T1 true ATE372785T1 (de) 2007-09-15

Family

ID=15961945

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00940773T ATE372785T1 (de) 1999-06-21 2000-06-21 Verfahren zur verabreichung von arzneimitteln mit bindungsaffinität zum plasmaprotein und verwendung der zusammensetzung in dem verfahren

Country Status (8)

Country Link
US (2) US7029653B1 (de)
EP (1) EP1197227B9 (de)
JP (1) JP4343473B2 (de)
AT (1) ATE372785T1 (de)
CA (1) CA2376159C (de)
DE (2) DE60036382T4 (de)
ES (1) ES2290042T3 (de)
WO (1) WO2000078352A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078352A1 (fr) * 1999-06-21 2000-12-28 Nihon Medi-Physics Co., Ltd. Procede d'administration de medicaments possedant une affinite de liaison aux proteines plasmatiques et preparation utilisee pour la mise en oeuvre dudit procede
AU2003262025A1 (en) * 2002-09-12 2004-04-30 Nihon Medi-Physics Co., Ltd. Preparation for controlling binging of drug to plasma protein
WO2004040309A1 (ja) * 2002-10-31 2004-05-13 Nihon Medi-Physics Co., Ltd. 薬物の血漿蛋白結合における血漿蛋白質上の結合部位の測定法及び血漿蛋白質変異の測定法
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
US9321095B2 (en) 2010-06-30 2016-04-26 General Electric Company Apparatuses and methods for cutting porous substrates
HUE047974T2 (hu) * 2014-03-13 2020-05-28 Stevanato Group Int A S Eljárás folyékony hatóanyag-készítmény kezelésére
CN117030905B (zh) * 2023-10-09 2024-01-05 成都华西海圻医药科技有限公司 一种快速定量血浆中丁二酮浓度的lc-ms/ms分析方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520112A (en) * 1983-03-09 1985-05-28 The Johns Hopkins University Assay method for organic calcium antagonist drugs and a kit for such an assay
US4642284A (en) 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US4976950A (en) * 1988-12-19 1990-12-11 The Dow Chemical Company Bone marrow suppressing agents
US5792444A (en) 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US6022541A (en) 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
CA2250295C (en) * 1996-03-12 2008-12-30 Pg-Txl Company L.P. Water soluble paclitaxel prodrugs
DE19648629A1 (de) 1996-11-12 1998-05-14 Meisegeier Bernhard Dr Verfahren zur immunologischen Erfassung und Produktion von Antikörpern
WO2000078352A1 (fr) * 1999-06-21 2000-12-28 Nihon Medi-Physics Co., Ltd. Procede d'administration de medicaments possedant une affinite de liaison aux proteines plasmatiques et preparation utilisee pour la mise en oeuvre dudit procede

Also Published As

Publication number Publication date
EP1197227A4 (de) 2002-12-04
DE60036382D1 (de) 2007-10-25
EP1197227B9 (de) 2008-06-11
DE60036382T4 (de) 2008-09-25
EP1197227A1 (de) 2002-04-17
JP4343473B2 (ja) 2009-10-14
CA2376159C (en) 2010-09-14
DE60036382T2 (de) 2008-06-12
ES2290042T3 (es) 2008-02-16
WO2000078352A1 (fr) 2000-12-28
CA2376159A1 (en) 2000-12-28
US7029653B1 (en) 2006-04-18
US20060140857A1 (en) 2006-06-29
EP1197227B1 (de) 2007-09-12

Similar Documents

Publication Publication Date Title
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
ATE361073T1 (de) Neue formulierungen zur transdermalen verabreichung von pergolid
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DE3879853T2 (de) Klebstoffzusammensetzung, Zusammensetzung mit kontrollierter Wirkstofffreisetzung und System zur transdermalen Anwendung von Arzneien.
DE69918296D1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
ATE108680T1 (de) Therapeutisches system zur verzögerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen (ii).
DE69533112D1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
BG103552A (en) Therapeutical forms
EE04800B1 (et) Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
ATE259226T1 (de) Zusammmensetzungen und verfahren zur verminderung der atmungsdepressionen und begleitender nebenmwirkungen von mu-opioid-verbindungen
ATE109000T1 (de) System zur freisetzung von medikamenten und dessen herstellungsmethode.
BR0316004A (pt) Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina
ATE325606T1 (de) Dosisform mit ansteigender dosisfreisetzung
TR200000149T2 (tr) Serebral nörovasküler bozuklukların, müsküler baş ağrılarının önlenmesine yönelik kompozisyonlar
ATE372785T1 (de) Verfahren zur verabreichung von arzneimitteln mit bindungsaffinität zum plasmaprotein und verwendung der zusammensetzung in dem verfahren
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
MX9706689A (es) Tratamiento de trastornos causados por el factor de crecimiento de citocina.
DK393188A (da) Farmaceutisk praeparat til intranasal administrering
ATE228843T1 (de) Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit
ATE245998T1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE59611212D1 (de) Transdermales therapeutisches system zur verabreichung von (s)-3-methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen salze
DE60028207D1 (de) Transdermales therapeutisches system zur verabreichung von calciumantagonisten
DE69808287T2 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties